- Global Operation
- Contract Manufacturing
Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli.
Chronic Hepatitis C
Peginterferon alfa-2a, alone or in combination with Ribavirin, is indicated for the treatment of patients 5 years of age and older with Chronic Hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha.
Chronic Hepatitis B
Peginterferon alfa-2a is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation.
Pegferon® 180 prefilled syringe injection: Each box contains 1 pre-filled syringe containing 0.5 ml sterile solution of Peginterferon alfa-2a 180 micrograms and an alcohol pad.